Evidence map›Paper›PMID 41657779›Full record

ReviewFrontiers in pharmacology2025

Natural products targeting the MAPK signaling pathway: potential options for ulcerative colitis treatment.

Canglin Li, Zuoqiang Li, Ya Zheng

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Anti-Inflammatory Components ofFoods (Basel, Switzerland) · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Canglin LiMedical Management Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Zuoqiang LiDepartment of Traditional Chinese Medicine, Shandong Academy of Occupational Health and Occupational Medicine, Jinan, China.
Ya ZhengThe Second Gastroenterology Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a chronic, recurrent inflammatory bowel disease, ulcerative colitis (UC) poses significant clinical challenges due to its progressive intestinal mucosal damage, recurrent exacerbations of abdominal pain and diarrhea, and increased risk of colorectal cancer conversion with disease duration. Conventional medications such as aminosalicylates and glucocorticoids can control inflammation in the short term, but long-term use often leads to issues like drug resistance, gastrointestinal adverse reactions, and immunosuppression, failing to meet patients' demand for safe, long-lasting treatment. Natural products, with their wide sources, diverse structures, and rich bioactivity, offer advantages such as multi-targeted effects, low toxicity, and minimal side effects. They demonstrate great potential in treating inflammatory diseases, providing new avenues for UC therapy. Recent studies indicate that various natural products which include flavonoids, alkaloids, terpenoids, and polyphenols can effectively suppress intestinal inflammatory responses, improve intestinal barrier function, and regulate immune balance by targeting the MAPK signaling pathway. This review, using the keywords "ulcerative colitis," "MAPK," and "natural products," retrieved relevant studies from PubMed, Web of Science, and CNKI databases over the past decade. This work identified 42 studies (32 from the past 5 years and 10 from the past 12 years), revealing the mechanisms by which natural products targeting the MAPK signaling pathway function in UC treatment. It provides important theoretical and experimental foundations for developing novel UC treatment strategies based on natural medicines and lays the groundwork for subsequent clinical translation studies of natural products.

Indexed as

inflammationintestinal barrierMAPKnatural productsulcerative colitis

Identifiers

PMID41657779
PMCPMC12872841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.